Analogic (Nasdaq: ALOG) reported earnings on June 6. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended April 30 (Q3), Analogic missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew significantly.

Gross margins dropped, operating margins expanded, net margins expanded.

Revenue details
Analogic recorded revenue of $121.3 million. The three analysts polled by S&P Capital IQ expected net sales of $128.0 million on the same basis. GAAP reported sales were 3.5% higher than the prior-year quarter's $117.2 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.76. The three earnings estimates compiled by S&P Capital IQ averaged $0.65 per share. GAAP EPS of $0.59 for Q3 were 69% higher than the prior-year quarter's $0.35 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 36.9%, 80 basis points worse than the prior-year quarter. Operating margin was 8.1%, 320 basis points better than the prior-year quarter. Net margin was 6.0%, 230 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $142.3 million. On the bottom line, the average EPS estimate is $0.80.

Next year's average estimate for revenue is $514.9 million. The average EPS estimate is $2.78.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 49 members out of 60 rating the stock outperform, and 11 members rating it underperform. Among 14 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 10 give Analogic a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Analogic is outperform, with an average price target of $71.50.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Analogic performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.